| Cabotegravir (CABO); Rilpivirine (RILP) |
Suspension, Extended release |
II (Paddle) |
20 (CABO); 50 (RILP) |
0.5% w/v solution of cetyltrimethylammonium bromide (CTAB) in 140 mM McIlvaine buffer, pH 7.4 (CABO); 6.0% w/v Polysorbate 20 in 0.05 M Sodium Phosphate buffer, pH 7.4 (RILP) |
|
5, 10, 15, 20, 30, 45 and 60 (CABO); 5, 30, 90 and 360 (RILP) |
2023/05/18 |
| Cabotegravir Sodium |
Tablet |
II (Paddle) |
60 |
0.01N HCl with 0.2% cetyltrimethylammonium bromide (CTAB) |
1000 |
5, 10, 15, 20, 25 and 30 |
2022/07/07 |
| Cabozantinib S-Malate |
Capsule |
II (Paddle) with sinker |
75 |
0.01 N HCl with 0.5% Triton X-100 (degassed) |
900 |
5, 10, 15, 20 and 30 |
2016/06/02 |
| Cabozantinib S-Malate |
Tablet |
II (Paddle |
75 |
0.01 N HCl with 0.375% Triton X-100 (degassed) |
900 |
5, 10, 15, 20 and 30 |
2016/07/28 |
| Caffeine; Ergotamine Tartrate |
Suppository |
II (Paddle) |
50 |
1% Tartaric Acid |
900 |
10, 15, 30, 35, 40 and 45 |
2024/02/05 |
| Calcifediol |
Capsule (Extended Release) |
II (Paddle) with sinker |
75 |
0.5% SDS in 5 mM Sodium Dihydrogenphosphate Monohydrate, pH 6.8 |
500 |
1, 2, 4, 6, 8, 10 and 12 hours |
2016/10/20 |
| Calcitriol |
Capsule |
|
|
Develop a quantitative rupture test |
|
|
2008/06/03 |
| Calcium Acetate |
Capsule |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Calcium Acetate |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Calcium carbonate/Famotidine/ Magnesium hydroxide |
Tablet, Chewable |
III (Reciprocating Cylinder) |
|
0.1 M Sodium Acetate, pH 4.5 |
900 |
5,10, 15, 20, 30 and 45 |
2023/03/30 |
| Canagliflozin |
Tablet |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Canagliflozin (Can)/ Metformin HCl (Met) |
Tablet (Extended Release) |
Met: I (Basket, 40 mesh): Can: I (Basket, 10 mesh [with option of tablet holder]) |
Met: 100: Can:100 |
Met: Simulated Gastric Fluid [SGF] without enzyme, pH 1.2; Can: 0.1% (w/v) polysorbate 20 in 0.05 M sodium phosphate buffer pH 6.8 ( 50 mg); 0.2% (w/v) polysorbate 20 in 0.05 M sodium phosphate buffer pH 6.8 (150 mg) |
Met: 900: Can: 900 |
Met: 1, 2, 4, 6, 8 10 and 12 hours: Can: 10, 15, 20, 30, 45 and 60 minutes; |
2016/12/22 |
| Canagliflozin/Metformin HCl |
Tablet |
II (Paddle) |
Canagliflozin: 75; Metformin: 50 |
Canagliflozin (50 mg): 0.025 %
Polysorbate 20; Canagliflozin (150 mg):0.075 %
Polysorbate 20; Metformin: Phosphate
buffer, pH 6.8 |
Canagliflozin (50 mg): 900; Canagliflozin (150 mg): 900 ; Metformin: 1000 |
Canagliflozin: 10, 15, 20, 30 and 45; Metformin: 5, 10, 15, 20 and 30 |
2015/05/28 |
| Candesartan Cilexetil (16 mg, 8 mg and 4 mg) |
Tablet |
II (Paddle) |
50 |
0.35% Polysorbate 20 in 0.05 M Phosphate Buffer, pH 6.5 |
900 |
10, 20, 30, 45 and 60 |
2007/06/20 |
| Candesartan Cilexetil (32 mg) |
Tablet |
II (Paddle) |
50 |
0.70% Polysorbate 20 in 0.05 M Phosphate Buffer, pH 6.5 |
900 |
10, 20, 30, 45 and 60 |
2007/06/20 |
| Candesartan Cilexetil/Hydrochlorothiazide (16/12.5 mg) |
Tablet |
II (Paddle) |
50 |
0.35% Polysorbate 20 in phosphate buffer pH 6.5 |
900 |
10, 20, 30, 45 and 60 |
2010/01/29 |
| Candesartan Cilexetil/Hydrochlorothiazide (32/12.5 mg and 32/25 mg) |
Tablet |
II (Paddle) |
50 |
0.70% Polysorbate 20 in phosphate buffer pH 6.5 |
900 |
15, 20, 30, 45 and 60 |
2010/01/29 |
| Capecitabine |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Capivasertib |
Tablet |
II (Paddle) |
60 |
Simulated Gastric Fluid without enzyme, pH 1.2 |
900 |
10, 15, 20, 30 and 45 |
2025/02/24 |
| Capmatinib HCl |
Tablet |
I (Basket) |
75 |
0.01N HCl (degassed) |
900 |
5, 10, 15, 20, 30 and 45 |
2022/05/12 |
请输入需要查询的英文药品通用名称，至少3个字符.